DEINOVE announced having signed a Memorandum of Understanding (MoU) with Sharon Laboratories. It aims at entering into an exclusive partnership for the development and marketing of a range of new bio-based solutions, including bioactives, arising from DEINOVE’s platform. This collaborative R&D program will benefit from DEINOVE's accumulated expertise in leveraging the properties of its collection of rare microorganisms. It will expand the potential of DEINOVE's biotechnology platform to a substantial and promising market, building on Sharon Laboratories 40 years of experience in the personal care preservation field. As the natural cosmetics segment continues to grow, the demand for such ingredients will grow with it. The draft agreement grants an exclusivity in various ingredient and functions to Sharon Laboratories, keeping DEINOVE's free to develop additional collaborations. DEINOVE and Sharon Laboratories have signed an MoU for an agreement to be finalized by the end of the first quarter of 2020. This decisive agreement has an initial term of 3 years and provides for the regular payment of significant milestones, amounting to several millions of dollars, as well as royalties on sales once commercialized. Sharon Laboratories demonstrates its commitment with the immediate $200,000 payment.